

SB-743921

Catalog No: tcsc0233



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

940929-33-9

Formula:

$C_{31}H_{34}Cl_2N_2O_3$

Pathway:

Cytoskeleton; Cell Cycle/DNA Damage

Target:

Kinesin; Kinesin

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

553.52

Product Description


SB-743921 is a potent inhibitor of the mitotic **kinesin KSP (Eg5)**, with a K_i of 0.1 nM.

IC50 & Target: K_i : 0.1 nM (Eg5)^[1]

In Vitro:

SB-743921 is a potent inhibitor of Eg5, with a K_i of 0.1 nM^[1]. SB-743921 (1 nM) potently inhibits colony forming cell (CFC) formation of chronic myeloid leukemia (CML) primary cells, but exhibits slight inhibitory activities on the colony-forming ability of normal bone marrow progenitors. SB-743921 (1, 3 nM) induces apoptosis of CML primary CD34 + cells, and shows slight effect on normal CD34 + cells. SB-743921 (2 nM) in combination with imatinib displays additive anti-proliferative effect in KCL22 and CML CD34 + cells. Furthermore, SB-743921 overcomes imatinib resistance in CML cells. SB-743921 (0.5 nM, 1 nM, 3 nM) inhibits MEK/ERK and AKT signaling in CML cells^[2].

In Vivo: SB-743921 has good oral bioavailability and pharmacokinetics and induces complete tumor regression in nude mice bearing lung cancer patient xenografts^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!